AFC manufacturers
- Arazine
-
- $106.00 / 1mg
-
2026-01-05
- CAS:135304-07-3
- Min. Order:
- Purity: 90.00%
- Supply Ability: 10g
- Arazine
-
- $106.00 / 1mg
-
2025-07-10
- CAS:135304-07-3
- Min. Order:
- Purity: 90%
- Supply Ability: 10g
|
| Product Name: | AFC | | Synonyms: | AFC;AC-CYSTEINE(FARNESYL)-OH;AC-CYS(FARNESYL)-OH;ACETYL-S-FARNESYL-L-CYSTEINE;N-ACETYL-S-(3,7,11-TRIMETHYL-2E,6E,10-DODECATRIENYL)-L-CYSTEINE;N-ACETYL-S-FARNESYL-L-CYSTEINE;N-ALPHA-ACETYL-S-FARNESYL-L-CYSTEINE;n-acetyl-s-farnesylcysteine | | CAS: | 135304-07-3 | | MF: | C20H33NO3S | | MW: | 367.55 | | EINECS: | | | Product Categories: | | | Mol File: | 135304-07-3.mol |  |
| Boiling point | 566.1±50.0 °C(Predicted) | | density | 1.038±0.06 g/cm3(Predicted) | | storage temp. | -15°C | | solubility | Soluble in DMSO (up to 25 mg/ml) or in Ethanol (up to 25 mg/ml) | | pka | 3.31±0.10(Predicted) | | form | Pale yellow oil. | | color | Yellow | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. | | Cosmetics Ingredients Functions | SKIN CONDITIONING
REDUCING | | LogP | 5.860 (est) |
| Description | N-acetyl-S-farnesyl-L-Cysteine is a synthetic substrate for the isoprenylated protein methyltransferase (also known as S-adenosylmethionine-dependent methyltransferase). Because it is able to serve as a substrate for the methyltransferase, it effectively functions as an inhibitor of methylation of endogenous isoprenylated proteins. | | Chemical Properties | Yellow-red oil | | Uses | Arazine is an FTS (trans-Farnesylthiosalicylic Acid) compound, which does not inhibit EJ cell growth and does not affect Ras. | | Definition | ChEBI: Acetyl-farnesyl-cysteine is a sesquiterpenoid. | | in vivo | Arazine (AFC) (2,000?μg/20?μl; applied on ear) produces a dose-dependent inhibition of the TPA-induced edema, with the maximal reduction of edema approaching 73%, with a 50% effective dose (ED50) of 55±12?μg/20?μl[1]. | Animal Model: | TPA-induced ear acute inflammation in mouse[1] | | Dosage: | 2000?μg/20?μl | | Administration: | 2000?μg/20?μl; Applied on ear | | Result: | Inhibited ear edema, as measured by ear weight. |
| | References | [1] C VOLKER. Effects of farnesylcysteine analogs on protein carboxyl methylation and signal transduction.[J]. The Journal of Biological Chemistry, 1991, 266 32: 21515-21522.
[2] Y XU. Inhibition of capacitative Ca2+ entry into cells by farnesylcysteine analogs.[J]. Molecular Pharmacology, 1996, 50 6: 1495-1501.
[3] J. ROSADO S S. Farnesylcysteine analogues inhibit store-regulated Ca2+ entry in human platelets: evidence for involvement of small GTP-binding proteins and actin cytoskeleton.[J]. The Ukrainian Biochemical Journal, 2000, 13 1: 183-192. DOI:10.1042/bj3470183
[4] JOEL S. GORDON . Topical N-acetyl-S-farnesyl-L-cysteine Inhibits Mouse Skin Inflammation, and Unlike Dexamethasone, its Effects Are Restricted to the Application Site[J]. Journal of Investigative Dermatology, 2008, 128 3: Pages 643-654. DOI:10.1038/sj.jid.5701061
[5] KATAYUN ADHAMI. N-acetyl-S-farnesyl-l-cysteine suppresses chemokine production by human dermal microvascular endothelial cells[J]. Experimental Dermatology, 2012, 21 9: 700-705. DOI:10.1111/j.1600-0625.2012.01562.x |
| | AFC Preparation Products And Raw materials |
|